February 1, 1998Canadian Journal of Physiology and Pharmacology

Analysis of effects of bosentan (Ro 47-0203), a nonpeptide endothelin ETA/ETB receptor antagonist, in the hind-limb vascular bed of the cat

View Full Paper

Ask AI

Bookmark

Population

Cat hind-limb vascular bed model

Design

Preclinical

Authors

HCHunter C. ChampionHeart Failure & Transplant LELance S. EstradaDefense Threat Reduction Agency LEL N Estrada

Discussion

Member takes

Implication

Does not inform human therapy; leaves open endothelin's mediation of angiotensin II responses for further study.

Structured PICO

Population

Cat hind-limb vascular bed model

Intervention

Bosentan (Ro 47-0203)

Outcome

Changes in hind-limb perfusion pressure in response to endothelin-1, sarafotoxin 6c, angiotensin II, and arginine vasopressinsurrogate

Bosentan attenuates vascular responses to endothelin-1 and low-dose angiotensin II in the cat hind-limb, suggesting endothelin's role in mediating angiotensin II responses and maintaining baseline vascular tone.

Cite This Study

Champion et al. (1998) studied this question.

synapsesocial.com/papers/6a815e8cadfa6baaaee1cf5a https://doi.org/10.1139/y98-001

View Full Paper

Ask AI

Bookmark

Analysis of effects of bosentan (Ro 47-0203), a nonpeptide endothelin ETA/ETB receptor antagonist, in the hind-limb vascular bed of the cat

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Analysis of effects of bosentan (Ro 47-0203), a nonpeptide endothelin ETA/ETB receptor antagonist, in the hind-limb vascular bed of the cat

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider